TPTX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 8.60%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Turning Point Therapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Turning Point Therapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Turning Point Therapeutics Share Price & Price History
Current Price: $76.01
Price Change: +0.30 (1.20%)
As of 09/8/2022 01:00 AM ET
Turning Point Therapeutics Insider Trading History
Turning Point Therapeutics Institutional Trading History
Data available starting January 2016
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More on Turning Point Therapeutics
Today's Range
Now: $76.01
52 Week Range
Now: $76.01
Volume
4,322 shs
Average Volume
1,137,726 shs
Market Capitalization
$3.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A